RTOG News

Long-term follow-up results of the NRG Oncology trial NSABP B-31 have shown that the addition of trastuzumab to adjuvant chemotherapy does not negatively affect cardiac function in women with node-positive, human epidermal growth factor receptor 2 (HER2)-positive, early-stage breast cancer who survive without cancer recurrence. Both patients who received trastuzumab in addition to chemotherapy and patients who received chemotherapy only maintained good cardiac function. Results of this follow-up analysis were published online in the Journal of Clinical Oncology.